Daily Chart Analysis on SYNGENE on 11092025Technical Analysis (Daily Chart)
Trend & Price Action:
The stock is currently trading at ₹661, showing recovery from recent lows near ₹625. After a corrective phase, buyers are returning around key support zones.
Moving Averages:
Price has reclaimed 20-DMA & 50-DMA, indicating short-term strength.
Stock is attempting to cross 100-DMA (~₹665) which acts as immediate resistance.
200-DMA near ₹705 remains a bigger hurdle for medium-term uptrend.
Indicators:
RSI (14) ~52: Neutral, showing recovery momentum but not yet overbought.
MACD: Bearish crossover still intact, though histogram shows narrowing, hinting at a possible reversal.
Parabolic SAR: Recent candles show buy signal formation as dots shift below price.
Support & Resistance Levels:
Support: ₹640, followed by ₹625.
Resistance: ₹665 (immediate), then ₹690–705 (medium-term).
Technical View:
The stock is showing a short-term pullback. Sustaining above ₹665 could open room towards ₹690–705 levels. On the downside, ₹640 is key support; a break below may weaken momentum.
Fundamental View
Syngene is a leading contract research and manufacturing (CRAMS) company, offering integrated services in drug discovery, development, and manufacturing.
Backed by Biocon Group, it serves global pharma, biotech, agrochemical, and animal health companies.
Strengths: Strong global clientele, long-term contracts, R&D capabilities, focus on biologics and specialty chemicals.
Risks: Global regulatory scrutiny, forex fluctuations, client dependency, and pricing pressures.
Micro View (Company-specific)
Strong Order Book: Robust long-term partnerships with global innovators ensure visibility.
Capacity Expansion: New facilities & biologics capabilities to support growth.
Earnings Trend: Revenue growth steady in high single digits; margins improving with scale.
Short-term Risk: Delay in client R&D spending due to global macro slowdown.
Macro View (Sector & Economy)
India is emerging as a global hub for contract research & manufacturing due to cost advantages, skilled workforce, and regulatory compliance.
Global push towards outsourcing in pharma & biotech remains a long-term growth driver.
Macro headwinds like US/EU recession fears or weaker biotech funding may temporarily impact order flows.
Upcoming Events & Impact
Q2 FY26 Results (October 2025): Key focus on revenue growth, margin expansion, and order inflows.
Global Pharma Updates: Any pickup in US/EU biotech R&D spending will positively impact Syngene.
Regulatory Updates: Inspections & approvals at manufacturing facilities may act as catalysts.
Disclaimer
This report is prepared only for educational and informational purposes. It should not be considered as investment advice or a buy/sell recommendation. Stock market investments are subject to risks. Past performance does not guarantee future returns. Please consult a SEBI-registered investment advisor before making any investment decisions.
Disclosure
The author/analyst has no personal or family holdings in Syngene International Ltd. Views are based on technical chart studies and publicly available data.
For More Info:
Visit Us- www.investogainerresearch.com
Calls Us- 9009099805, 9098804206
Email- info@investogainerresearch.com